as 10-28-2024 4:00pm EST
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Upcoming Earnings Alert:
Get ready for potential market movements as argenx SE ARGX prepares to release earnings report on 31 Oct 2024.
Founded: | 2008 | Country: | Netherlands |
Employees: | N/A | City: | N/A |
Market Cap: | 26.5B | IPO Year: | 2017 |
Target Price: | $551.22 | AVG Volume (30 days): | 188.0K |
Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.47 | EPS Growth: | N/A |
52 Week Low/High: | $327.73 - $571.97 | Next Earning Date: | 10-31-2024 |
Revenue: | $1,659,620,000 | Revenue Growth: | 98.69% |
Revenue Growth (this year): | 61.36% | Revenue Growth (next year): | 42.16% |
ARGX Breaking Stock News: Dive into ARGX Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Simply Wall St.
11 days ago
Insider Monkey
13 days ago
MT Newswires
14 days ago
GlobeNewswire
14 days ago
GuruFocus.com
20 days ago
Zacks
22 days ago
Zacks
25 days ago
The information presented on this page, "ARGX argenx SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.